Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: protocol for a secondary Bayesian analysis

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Investigating the use of physical restraint of children in emergency departments: A Scandinavian survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effects of adding quinolones to beta-lactam antibiotics for sepsis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Does rocking motion calm delirious patients in ICU? A multicentre randomised clinical trial protocol (RockingICU)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Iatrogenic withdrawal syndrome frequently occurs in paediatric intensive care without algorithm for tapering of analgosedation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Is clinical heterogeneity the foremost prominent threat to the validity of meta-analyses?

    Research output: Contribution to journalEditorialResearchpeer-review

  1. Associations between maternal and environmental exposures on atopic disease in the offspring of mothers with asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Coronavirus disease 2019 (COVID-19) can lead to severe hypoxic respiratory failure and death. Corticosteroids decrease mortality in severely or critically ill patients with COVID-19. However, the optimal dose remains unresolved. The ongoing randomised COVID STEROID 2 trial investigates the effects of higher vs lower doses of dexamethasone (12 vs 6 mg intravenously daily for up to 10 days) in 1,000 adult patients with COVID-19 and severe hypoxia.

METHODS: This protocol outlines the rationale and statistical methods for a secondary, pre-planned Bayesian analysis of the primary outcome (days alive without life support at day 28) and all secondary outcomes registered up to day 90. We will use hurdle-negative binomial models to estimate the mean number of days alive without life support in each group and present results as mean differences and incidence rate ratios with 95% credibility intervals (CrIs). Additional count outcomes will be analysed similarly and binary outcomes will be analysed using logistic regression models with results presented as probabilities, relative risks and risk differences with 95% CrIs. We will present probabilities of any benefit/harm, clinically important benefit/harm and probabilities of effects smaller than pre-defined clinically minimally important differences for all outcomes analysed. Analyses will be adjusted for stratification variables and conducted using weakly informative priors supplemented by sensitivity analyses using sceptic priors.

DISCUSSION: This secondary, pre-planned Bayesian analysis will supplement the primary, conventional analysis and may help clinicians, researchers and policymakers interpret the results of the COVID STEROID 2 trial while avoiding arbitrarily dichotomised interpretations of the results.

TRIAL REGISTRATION: NCT04509973; EudraCT: 2020-003363-25.

Original languageEnglish
JournalActa Anaesthesiologica Scandinavica
Issue number5
Pages (from-to)702-710
Number of pages9
Publication statusPublished - May 2021

    Research areas

  • Bayes Theorem, COVID-19/drug therapy, Dexamethasone/administration & dosage, Humans, Hypoxia/drug therapy, Randomized Controlled Trials as Topic, SARS-CoV-2

ID: 62295867